X. Cheng

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

Wei Wei, Xiaosu Zhu, Jibin Li, 2022, Journal for ImmunoTherapy of Cancer.

Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma

H. Abel, L. Ratner, J. Harding, 2016, Blood Cancer Journal.

Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.

Wei Wei, Jibin Li, Yong-wen Huang, 2021 .